The Korea National Enterprise for Clinical Trials (KoNECT) said Wednesday that it would operate the Korean Pavilion at the American Society of Clinical Oncology’s annual conference (ASCO 2024), which will be held from May 31 to June 4, local time, at McCormick Place in Chicago, Ill.
ASCO is the largest clinical oncology conference in the United States and one of the top three cancer societies in the world. It is attended by about 42,000 professionals, including R&D and licensing executives from pharmaceutical and biotech companies, oncologists, and regulatory officials worldwide, with more than 200 sessions scheduled to be presented this year.
KoNECT has run a national booth at ASCO since 2016. This year, 11 organizations will move into the Korean Pavilion, including domestic pharma and biotech companies, CROs, consulting firms, data solution companies, and clinical trial centers. For instance, Hanmi Pharmaceutical, a major Korean drugmaker, and Qurient and GI Innovation, which are conducting global clinical development, will showcase their development status.
The government agency will provide space for publicity and business meetings to corporate participants as part of the Korean delegation and research data on more than 100 global companies participating in ASCO. It will also help participating companies to expand their U.S. advance by connecting them with business meetings on-site, according to KoNECT officials.
In addition, it plans to hold partnership meetings with 30 foreign anticancer drug developers that have yet to land in Korea, including Agios, Arcellx, Day 1, Genmab, Summit, and Telix, along with consultants specializing in licensing, to discuss consulting support for attracting domestic clinical trials.
"There is a growing demand from Korean companies to support global collaboration at the government level," KoNECT Chairman Park In-seok said. "KoNECT will continue to attract global clinical trials and actively support successful clinical trials and new drug development through global collaboration with domestic companies."